---
title: "Century Therapeutics to present CNTY-813 type 1 diabetes preclinical data at EASD 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292195235.md"
description: "Century Therapeutics will present preclinical data for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes engineered with Allo-Evasion 5.0, at two upcoming conferences: EASD 2026 in Milan and the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia."
datetime: "2026-07-09T12:01:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292195235.md)
  - [en](https://longbridge.com/en/news/292195235.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292195235.md)
generator: "portal-rs"
---

# Century Therapeutics to present CNTY-813 type 1 diabetes preclinical data at EASD 2026

-   Century Therapeutics secured oral presentation slots for preclinical CNTY-813 data at EASD 2026 in Milan. \* A second oral presentation will take place at Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia. \* CNTY-813 is an iPSC-derived islet replacement program engineered with Allo-Evasion 5.0 for type 1 diabetes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090800PRIMZONEFULLFEED9759406) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)

## Related News & Research

- [Century Therapeutics Reports Q2 Results, Pipeline Advancements](https://longbridge.com/en/news/295668584.md)
- [Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics](https://longbridge.com/en/news/296641838.md)
- [Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress](https://longbridge.com/en/news/296615069.md)
- [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md)
- [Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi](https://longbridge.com/en/news/296182772.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**